相关实验视频

Updated: Jun 27, 2025

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay

Published on: February 9, 2021

新型螺旋环滴度剂,SpiD3,准慢性淋巴细胞白血病的生存途径,具有强大的临床前效应

Alexandria P Eiken¹, Audrey L Smith¹, Sydney A Skupa¹

¹Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, Nebraska.

Cancer research communications

|April 30, 2024

概括

SpiD3通过破坏B细胞受体 (BCR) 信号和激活未折叠蛋白质反应 (UPR) 来有效向慢性淋巴细胞白血病 (CLL). 这种新型药物显示出对抗易布鲁替尼抗性CLL的前景,提供了一种新的治疗途径.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
药理学药理学是指药理学的学科.

背景情况:

慢性淋巴细胞白血病 (CLL) 细胞存活依赖于B细胞受体 (BCR) 信号和瘤微环境 (TME) 内的未折叠蛋白反应 (UPR).
现有的布鲁顿氨酸激酶 (BTK) 抑制剂,如易布鲁替尼,可以提高生存率,但由于突变或替代生存途径而面临抗药性.
恶性细胞中基础UPR升高为诱导错误折叠蛋白质积累的药物提供了治疗窗口.

研究的目的:

评估SpiD3的疗效,一种新型的螺旋环二聚体,对CLL细胞,包括耐易布鲁替尼的模型.
阐明SpiD3抗白血病作用背后的分子机制.
评估Spid3在临床前CLL小鼠模型中的治疗潜力.

主要方法:

在CLL细胞系,来自患者的CLL样本和耐易布鲁替尼的CLL细胞上进行了综合的多组和功能分析.
研究包括评估CLL的Eμ-TCL1小鼠模型.
试验重点关注的途径,如BCR信号传递,NFκB信号传递,和内质网膜压力.

主要成果:

斯皮迪3调节了关键通路,包括BCR信号传递,NFκB信号传递和内分泌网膜应激.
斯皮迪3诱导了UPR上调和抑制了CLL细胞中的全球蛋白质合成.
在Eμ-TCL1小鼠模型中,SpiD3在ibrutinib耐药的CLL细胞中显示出抗白血病作用,并降低了瘤负担.

结论:

斯皮迪3有效地针对关键的CLL漏洞,包括NFκB信号和UPR,独立于TME刺激.
斯皮迪3表现出强大的抗瘤特性,并保留了对耐药性CLL的有效性.
斯皮迪3代表了对CLL的有前途的新型治疗剂,特别是在耐易布鲁替尼的病例中.

更多相关视频

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

相关概念视频

Abnormal Proliferation

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...

The Intrinsic Apoptotic Pathway

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

The JAK-STAT Signaling Pathway

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...